Delcath Systems (DCTH) Q3 2026 earnings review
Delcath sales jump past its plan, but center openings lag
Delcath Systems, the maker of the HEPZATO liver-cancer chemotherapy system, grew straight through the summer instead of repeating last year's seasonal slowdown. Third-quarter sales rose 71% from a year ago to $35 million, well above what the company's own prior plan pointed to, and operating profit reached $7 million. Chief executive Gerard Michel raised the full-year outlook by $10 million, though by our math the new plan has fourth-quarter sales dropping to about $27 million.
| Revenue | $35.1M +71% from a year ago |
|---|---|
| HEPZATO kit volume | +72% from a year ago |
| Operating income | $7.1M 20% of revenue vs -2% a year ago |
| Full-year revenue outlook | Raised $10M middle of the range: $116M (+36%) |
⚖️ Verdict: 🟢 Bullish
The story got better because existing hospitals treated many more patients and the one-year anniversary of hospital price discounts removed the drag on revenue. Higher sales also turned the business solidly cash-generative, adding $8 million from operations to pay for clinical trials. One caution: Delcath opened only two new centers this quarter, and its trials in breast and colorectal cancer remain slow to enroll.
The question now is whether the fourth-quarter drop implied by the full-year plan reflects real holiday scheduling slowdowns or another cautious target. If doctors are starting more patients per center, fourth-quarter sales will stay near third-quarter levels; if summer volume borrowed from autumn, sales will step down. Next quarter's revenue and new patient start rate will settle it.
🐂 Bull Case
Summer Volume Grew Instead of Slowing
Delcath sells HEPZATO KIT, a drug-and-device system that delivers high-dose chemotherapy directly to the liver while filtering the patient's blood. Last year, summer vacations slowed new patient scheduling in the third quarter. Three months ago, the company's full-year outlook pointed by our math to $24.9–26.9 million in average quarterly revenue for the second half, below the second quarter's $29.1 million.
Instead of slowing down, sales jumped to $35.1 million, up 20.5% from the second quarter and 70.7% from a year ago. HEPZATO treatment volume rose 72% from last year. "Growing physician experience with HEPZATO, strong engagement across our treatment center network, and increasing interest in its use alongside systemic therapies reinforce our confidence in the long-term opportunity," chief executive Gerard Michel said.
That result tests Michel's claim and shows existing hospitals are treating more patients, because the cancer-treatment group added only two centers in the quarter. By our math, revenue per active US center rose to nearly $1 million in the quarter. However, beating the implied third-quarter target also shows the prior outlook was very cautious.
What to watch: fourth-quarter revenue against the $26.8 million implied by the middle of the new full-year outlook. Another beat would show the company is still setting cautious targets rather than facing a winter slowdown.
Hospital Discounts No Longer Hold Back Sales
On July 1, 2025, the medical-device maker began offering mandatory 340B government price discounts to qualifying US hospitals. For the past four quarters, those discounts meant revenue grew much more slowly than the number of treatment kits sold. In the second quarter, kit volume rose 30% from a year ago while US HEPZATO revenue grew 20.7%, a gap of more than 9 percentage points.
This quarter passed the one-year anniversary of that price cut. US HEPZATO revenue rose 69.4% from a year ago to $32.7 million, nearly matching the 72% growth in kit volume. By our math, the gap between volume growth and sales growth shrank to 2.6 percentage points, and gross margin expanded by 1.6 percentage points to 88.8%.
What to watch: the gap between full-year volume growth (planned at 41% or more) and full-year HEPZATO revenue growth next quarter. A small gap will confirm that newly opened academic hospitals are not pushing the average selling price lower.
Higher Sales Turn Into Operating Profit and Cash
Delcath aims to fund its clinical trials using cash from its commercial liver treatments. Earlier this year, rising trial and sales costs kept operating profit near breakeven despite high product margins. This quarter, revenue grew much faster than overhead, so operating margin jumped by 22.2 percentage points from a year ago to 20.3%, producing $7.1 million in operating income.
- Selling and administrative costs: $13.1 million, or 37.2% of revenue, down 13.1 percentage points from a year ago
- Research and development costs: $11.0 million, or 31.4% of revenue, down 7.5 percentage points from a year ago
- Operating cash flow: $8.2 million, up from $4.8 million a year ago and $5.7 million last quarter
- Cash and short-term investments: $104.3 million with no debt, up from $95.9 million in June
Cost of goods sold fell 1.6 percentage points of revenue even as the company paid for "increased clinical headcount and increased clinical trial activity" and "continued commercial expansion activities". Generating $8.2 million in cash from operations proves the commercial franchise can pay for expanding the trial pipeline without borrowing money or selling new shares.
What to watch: fourth-quarter operating expenses when the company reports full-year results. If revenue drops toward the $26.8 million implied by the full-year plan, fixed clinical costs will take a larger share of sales.
🐻 Bear Case
Hospital Openings Still Lag the Year-End Goal
Using HEPZATO requires a hospital to train a specialized team of doctors and technicians to isolate the liver and filter blood during chemotherapy. Delcath began the year aiming for 40 active US treatment centers by the end of 2026, then lowered that target to 37 in the spring after missing its original 2025 center goal as well.
The company reported 33 active treatment centers in this release, adding two centers during the third quarter after adding two in the second quarter. By our math, the oncology group must activate four centers in the final quarter of the year to reach its 37-center goal, which is double the pace of the past six months.
What to watch: the year-end active center count in the fourth-quarter report. Falling short of 37 would leave future growth even more dependent on existing hospitals treating more patients each month.
New Cancer Trials Move Slowly and Lack Numbers
HEPZATO is currently approved in the US only for metastatic uveal melanoma, a rare eye cancer that spreads to the liver, and it generated 93.2% of revenue this quarter. To grow beyond that single market, Delcath is testing the system in colorectal and breast cancers that have spread to the liver, aiming to enroll about 90 patients in each Phase 2 study.
Michel highlighted a "planned IND submission for cholangiocarcinoma in early 2027" (an application to begin human bile-duct cancer trials) and "completion of ongoing preclinical development of an oxaliplatin-based PHP product by mid-2027". Meanwhile, the breast cancer trial dosed its first patient on July 9, 2026, two quarters behind the original schedule, and the release gave no patient enrollment numbers for the colorectal study.
Adding early-stage projects for 2027 cuts against the idea of rapid pipeline progress when the two active Phase 2 trials are already running behind schedule and withhold enrollment counts. Because main readouts for colorectal and breast cancer are not due until 2028 and 2029, the business relies entirely on uveal melanoma for the next several years.
What to watch: cumulative patient enrollment and active screening sites for both Phase 2 trials on the conference call or in the quarterly filing. Continued silence on patient counts would signal that slow hospital recruiting is pushing trial results further out.
Risks this quarter didn't answer
Three standing concerns from prior quarters cannot be read from the earnings release alone and depend on the conference call or the quarterly filing.
- New patient starts per center each month: dropped from 0.7 in the first quarter to 0.5 in the second; the release did not give the third-quarter rate, which leads kit volume by one to three quarters.
- Customer concentration: the largest hospital customer accounted for 18.8% of first-half sales; the quarterly filing's footnote will show whether growth broadened across the 33 centers.
- Competing systemic trials: whether rival uveal melanoma drug studies are still pulling patients away before they receive liver-directed therapy requires commentary from the call.
💲 Other KPIs
Uncollected customer bills rose 26.8% from the second quarter and 72.1% since December, outpacing the 20.5% quarterly rise in product sales. Accounts receivable have climbed for three straight quarters from $11.7 million at year-end, holding back $4.3 million of working capital in the third quarter alone.
Weighted average diluted shares rose 3.2% from the second quarter and 2.4% from a year ago as a higher share price brought employee stock options into the count. Stock-based compensation was $4.2 million, or 12.1% of revenue, down from 17.6% in the second quarter.
Sales of CHEMOSAT, the device-only version sold in Europe, rose 84.6% from $1.3 million a year ago and 20.0% from $2.0 million in the second quarter. After hovering between $1.3 million and $2.0 million for six quarters, European sales reached their highest level of the launch.
🔮 Guidance
Raised. The middle of the full-year range moved up $10 million to $116 million, or 36.1% growth over 2025. By our math, subtracting nine-month sales of $89.2 million leaves $26.8 million for the fourth quarter—up 29.2% from a year ago, but down 23.7% from the third quarter. It is the second raise this year: unchanged in Q1, +$6M in Q2, and +$10M in Q3.
Raised. Management lifted the floor for full-year US kit volume growth by 13 percentage points after third-quarter volume grew 72% from a year ago. Because volume grew 36% in the first quarter and 30% in the second, the new 41% floor still allows for slower growth in the fourth quarter.
Raised. The company lifted the bottom of its full-year gross margin range by 1 percentage point, moving the middle of the range to 88.0%. Nine-month gross margin stands at 88.1% after hitting 88.8% in the third quarter. By our math, the middle of the outlook leaves fourth-quarter gross margin at 87.7%.
Unchanged. Delcath still plans to report positive full-year EBITDA excluding stock compensation. The target is already locked in, because nine-month adjusted EBITDA reached $22.5 million after generating $11.5 million in the third quarter alone.
❓ Key Questions
Why does the outlook imply a fourth-quarter sales drop?
By our math, the $115–117 million full-year plan leaves $25.8–27.8 million for the fourth quarter, down about 24% from the third quarter's $35.1 million. Did doctors pull autumn treatments into the summer, or is management building a large cushion?
What were monthly new patient starts per center?
The release did not report new patient starts per site each month, which fell from 0.7 in the first quarter to 0.5 in the second. Because each patient receives about four treatments across several months, third-quarter starts drive winter kit volume.
How many patients have enrolled in the colorectal trial?
Delcath reported 7 colorectal trial patients in the first quarter and gave no count in the second or third quarters. Investors need the current enrollment number out of the 90-patient target to judge whether the 2028 readout date still holds.
Does Delcath still expect 37 active centers by December?
The release updated revenue and volume targets but did not mention the 37 year-end center goal. With 33 active sites in November after adding two per quarter since March, hitting 37 requires doubling the activation pace in the final weeks.